Analysis of outcome from start of consolidation therapy. Kaplan-Meier estimates of PFS for bortezomib-treated patients vs controls (A), PFS for patients achieving ≥VGPR vs patients achieving <VGPR (B), PFS for patients in the <VGPR category at randomization (C), PFS for patients in the ≥VGPR category at randomization (D), and OS for bortezomib-treated patients vs controls (E).